day 14.
• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.
• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w